Thứ Ba, 8 tháng 1, 2019

Youtube daily Jan 8 2019

please subscribe our Channel and hit the bell icon to get update regularly in

this video, I will show you how to fix if your Google Play Store shows no internet

connection with three simple methods let's follow all the instruction of the

video first of all make sure your device has a good connection speed through a

web browser if it's fine then start the troubleshooting go to settings scroll

down and tap on more settings or applications tap on all or application

manager tap on all or swipe left until you find all tab scroll down and find

out the Google Play Store tap on it clear the cache then clear data tap on

uninstall update then ok uninstall after that move back to the home screen and

restart your device after the restart I hope your problem will be fixed method

number two go to my file or file manager

device storage delete the android folder hope this time

your problem will be fixed the next method is you need to remove your Google

Account and re-add it again go to settings scroll down and find out the

accounts or users tap on Google and remove your gmail account from here now

move back to homescreen and restart or reboot your device

after the restart open Play Store Henry add your gmail account by typing your

email and password you can add another gmail account here if you want that's it

if you found this video helpful then please consider a subscription to this

channel for the more helpful tutorial thanks for watching

For more infomation >> Google Play Store No Internet Connection Retry Problems [FIXED] - Duration: 2:56.

-------------------------------------------

Mitch McConnell Promises Even MORE Incompetent Judges Will Be Confirmed - Duration: 5:43.

Senate majority leader, Mitch McConnell knows that he can't accomplish much over the next

two years as Democrats now control the House.

So he said he's focusing on the one area where you can get things done and that unfortunately

is packing the court system.

You know, Farron, I don't know how many times we've talked about this and every time this

topic comes up for, I can remember during the Obama administration, you doing a segment,

you were outraged.

I was outraged by the fact that in the first two years where Obama could've confirmed a

lot of judges.

He sat on the hands.

Now there's a backstory to that.

A friend of mine, Howard Nations, who's a tremendous trial lawyer out of Texas, had

the chance to meet with Obama.

We had raised money for him.

The lawyers, a whole cadre of us raised some serious money.

And so Howard was talking to Obama and said, You know the appointments that you're making

are really bad.

The appointments that you're making are corporate lawyers that have done nothing except represent

corporations.

For the most part.

They've never represented injured victims.

They've never represented really the have nots in any kind of meaningful way.

They come up in the system representing Pfizer, Exxon, DuPont, Dow Corning, Raytheon, all

of the big companies.

These are the pointing, these are the, these are the judges, Mr. Obama that you're, President

Obama that you're pointing and it's mistake.

Obama's reaction was interesting.

Obama's reaction was, well, I don't understand what you mean.

You telling me a judge can't be fair simply because he came up that way?

And Howard said, yes sir.

That's what I'm telling you.

Pick up from there.

This story is even worse than that.

It is, and you know, with the trial lawyer magazine, the very first story we ever did

when Obama took office was about all of the judicial appointments he could be making.

The people he should be choosing.

We worked with the AAJ very closely.

They were meeting with him saying, here are some good ones, and then he just wouldn't

look at that list at all.

So he leaves office with well over 100 judicial vacancies, you know, to the point where it

was a judicial crisis is what they referred to it as because we had so few judges.

So Trump comes in with Mitch McConnell being fed things by the Federalist Society and they

have been, I think 85 at this point is how many total judges, including the two on the

supreme court that he's gotten through first two years, more than any other president.

In history, in the history of the business.

Right.

And Mitch McConnell says in an interview right after the midterms, he says, I'm not worried.

I've got two extra people in the Senate.

So now I can even lose a few more Republican votes and still ram these nominees right through

the process and get them on the court.

Let me double back on another topic you and I have talked about so often.

And that is, what is it that the DNC and DNC leadership focuses on when say, we need a

good judge?

It's always social issues in matter of fact HuffPost did a story.

They kinda got it.

I never have much confidence in the HuffPost.

This is another example of how little confidence I have in HuffPost.

The story focuses on, we're outraged because the judges that he's appointing are anti LGBT

and they're anti abortion and you're going, wait a second.

No.

The judges that he's appointing our judges that want to take away people's right to recover

when they, when a family member has been killed by a bad product or when a corporation has

stolen money from their pension program.

They don't even, they don't even see how that fits together.

HuffPost is a great example of the monotonous dribble that comes out of progressive media

that all we're going to focus on here, the whole focus or these judges are bad because

of their stance on LGBT.

What about they're bad because they're trying to do away with jury trials?

What about their bad because every time they get to rule, they rule with corporate America,

whether it's environmental, whether it's a, whether it's a civil rights, it's always the

same thing.

But the idiots that run the democratic machine are always about social issues and that's

the only, that's the only threat they see here.

I mean, that's literally the way this story reads.

What's your take?

It is, and you look at, you know, just take the last two years, the four biggest legal

stories that have been out there.

There's been the DuPont C8, Monsanto with Roundup, Johnson & Johnson with talc and the

opioid crisis.

Right.

About the four biggest ones out there.

These corporate judges...

Are going to make decisions.

Yeah.

You know, had they been in place at the time when some of these we're going through the

courts, these lawsuits that have recovered billions for the victims after these companies

lied for decades, those judgments wouldn't have existed.

They would have been overturned at the first...

Farron, you know what it is?

It's a lack of world experience.

It's a lack of life experience.

When you see these progressive writers, all they do, they focus on the easy, low hanging

social issues.

Yeah, we wish the judges would be better on social issues, but what about issues that

have to do with things like a corporation like Exxon?

We're going to do a story in a minute where they're trying to, they're trying to sell

more, more oil by changing the laws in America on fuel consumption.

How about that?

But it's almost as if these people who write and it infuriates me.

There's very few progressive sites I can even go to because the analysis is so poor.

This is one of them, HuffPost story on these judges.

Outrageous to me.

For more infomation >> Mitch McConnell Promises Even MORE Incompetent Judges Will Be Confirmed - Duration: 5:43.

-------------------------------------------

Live PD: Unexpected Subject (Season 3) | A&E - Duration: 2:50.

For more infomation >> Live PD: Unexpected Subject (Season 3) | A&E - Duration: 2:50.

-------------------------------------------

2019 Stock Market Outlook: Stocks to Watch, Trends, & Upcoming IPOs - Duration: 37:43.

Chris Hill: It's the Motley Fool Money radio show! I'm Chris Hill. Joining me in studio

this week, senior analysts Matt Argersinger and Aaron Bush. Happy new year, gentlemen!

It's our 2019 preview. We've got stocks to watch, stocks to avoid, CEOs on the hot seat,

and more. And, of course, a few reckless predictions, as always.

Before we get to the 2019 preview, though, I think we have to talk about Apple.

Shares of Apple falling 10% on Thursday after CEO Tim Cook warned investors first quarter revenue

was going to be about $5-$8 billion lower than previously expected. Several reasons

for that, Matty. The trade war in China, the economic slowdown in China, the battery replacement

program that they had last fall. This was still pretty shocking development.

Matt Argersinger: Lots of moving parts, but you're right. This was pretty bad. If you

look back to their guidance in early November, looking for between $89-$93 billion in revenue.

To come in, then, at $84 billion, $5 billion below the low end of your guided range,

that's a problem. CEO Tim Cook said that really 100% of the miss was due to China and a contraction

in the smartphone market there. That's a good excuse. It's probably the right excuse.

Investors have been questioning whether or not the iPhone, especially the latest versions of the iPhones

with the high price tags, could really penetrate the highly competitive smartphone market in China.

I think we're starting to see the fact that no, that's not really the case.

Aaron Bush: I don't think it's that surprising, actually, that Apple has China issues. I was

just thinking back, four years ago, when Matt and I were talking about China in the context

of our Supernova portfolio, talking about opportunities and concerns, China was a big

thing we were talking about. At the time, we realized that China is a big opportunity

simply because how many people are in that country, but we didn't necessarily expect it

to play out the same way as it did in the U.S. Since then, the stock is about roughly

flat with the market, which is interesting.  I think we started to see the cracks in the

foundation about two years ago. About that time is when I started studying Tencent,

which owns WeChat. It made me realize that iOS is far less important in China because WeChat

is an in-app operating system that people do everything in. So, the same type of competitive

advantage that Apple would have in the U.S. with iMessage, Notes, various services,

that doesn't exist in China. It showed in the data. At the time, the retention rate, people who

would have an iPhone that would buy another iPhone, outside of China it was over 80%.

In China, it was 50%, which is essentially a coin flip.

I think now, because of the economic turbulence that's starting to happen, trade wars, slowdown,

we're starting to see that play out at an accelerated rate. People who would be the

Apple buyers either already own them or did own them. Upgrade cycles are longer, and retention

is still sub-optimal. Apple just has mediocre market share, and I think that's not necessarily

going to change. Argersinger: I agree. As long as the iPhone

is such a large part of Apple's core business, they can talk about Services all they want,

but this is still a product that's about 70% of revenue and the majority of operating profits.

Now, I will say this, because we're positive people here at The Fool. Coming into this report,

Apple was already down about 40% from its high. Granted, it had a horrible day this week that

took it down even further. But even at the reduced earnings estimates now, you're

looking at a stock that's only trading about 11X-12X earnings. Certainly below the average

market multiple. Now, if earnings come down further, the stock could certainly follow suit.

But it's hard not to call it cheap right now.

Hill: That's the thing. Tim Cook talked about how he hadn't seen the December numbers,

therefore there's no way he's seen the January numbers, because they're not in yet.

Their first quarter report comes out in early February. If you're looking at this stock, and you're thinking,

"Boy, it looks cheap," do you buy here? Or you want to see what the actual numbers

are before you put down a little money to buy some stock?

Bush: Oh, I don't know. It sounds like another coin flip to me. We don't really know. I do think

that the valuation is somewhat compelling. You're betting that iPhone sales stabilize,

and you're betting that the Services segment can become much more than 15% of revenue,

which it is now. I think that most people think that is the case. Or, at least around here,

that's the bullish stance. Personally, I have some more questions.

When you have a monopoly taking 30% of every single transaction that goes on your ecosystem,

regulatory issues will one day be a concern. The same thing that we've seen with Alphabet, the same

thing we see with Facebook. One day, those same headlines are going to be going on with

Apple, too. And then the Services narrative will slowly not seem so amazing anymore.

Hill: Alright, let's get to our 2019 preview. Aaron, I'm going to start with you.

What is one industry you're going to be watching this year?

Bush: I'm really interested to be watching the ride sharing industry. With Uber and Lyft,

and maybe even DiDi, which is in China, IPO-ing in 2019, it's really exciting that public

market investors will finally have access to this new, massive, quickly growing industry.

I'm excited to see what the numbers look like. They probably won't be great from a

profitability perspective. But thinking about transportation as a service, and what that

means beyond just ride sharing, what it means for logistics with food, and are they going

to buy more bike and scooter companies? That type of thing. I'm really interested to

hear more about that longer-term game plan. We'll learn a lot about that in 2019.

Hill: Matty, what about you? Argersinger: It's always interesting,

but I think especially so this year, I'm going to be watching the social network,

social media space. We're already seeing for the first time ever a real, legitimate slowdown

in user growth and usage rates, especially if you look at the core Facebook platform.

My questions are, how does Facebook, how does Twitter, how do these companies solve

for all the privacy risks that people seem to be somehow aware of these days that they weren't

aware of years before? How do they prevent all the vile and deceptive behavior without

damaging free speech and freedom of expression on the platforms? These are big challenges.

Throwing money and bodies as we've seen Facebook do, I'm not sure that's going to solve it.

It's going to take a lot of innovation. I don't doubt Facebook and Twitter can do it,

but I think there's a real chance we actually see a tipping point in 2019 where the powerful

network effect that has sucked in so many users over the years to these platforms starts

to weaken, and we start to see meaningful declines in time spent on the platforms.

I think it'll cause a reset of the businesses. Hill: In terms of trends, Aaron, what's got

you excited in 2019? Bush: Augmented reality. I think it's been

a long time since we've had a big new consumer-facing technology to invest in. I have a hunch

that AR, and probably VR associated with it, is going to be one of the next big waves,

even though some of the hype around it seems to have fizzled out. I might be off by one year,

but 2019 could be the year in which good AR products are revealed by at least one major

tech company, probably Apple. For Apple, it makes sense. They've been acquiring companies

with AR tech since 2013. They released their AR kit, their developer toolkit in late 2017.

They have all the pieces in place, controlling the hardware and the software, plus the developer

community to make it happen. They probably recognize that winning over the AR market

might be as big of a deal one day as winning the smartphone wars was.

I'm a bit iffy on timing, but I'm really excited to see the pieces start to come together.

You never know, Apple might have a big AR glasses or something announcement and late 2019.

Argersinger: So, you're saying Apple has a chance? Bush: I'm saying that they need to do this.

Technology is going to shift past smartphones. Services won't be enough. Fingers crossed.

Hill: The cash that Apple has on the balance sheet, that probably also helps them sleep at night.

Argersinger: It helps a little bit. Hill: In terms of trends, Matty, what about you?

Argersinger: Big trend this year, the past year already but even bigger now this year,

sports betting taking off. I've been known to place a bet or two in my time. I think

there are broader implications for the economy. The world is far more efficient, far more

innovative when it becomes gamified. A competitive marketplace of ideas and dollars that are wagered,

inefficiencies tend to get streamlined out.

It's interesting. If you go back to this fall, you could place real money on which party

was going to lead the House of Representatives after the November election. You could have placed

money on where Amazon was going to open its second headquarters. We talked about

that on the show. Imagine betting on things like what the weather is going to be like tomorrow,

who's going to succeed Warren Buffett as CEO of Berkshire Hathaway, what's the over

and under on the minutes it's going to take for Domino's to deliver my pizza. These might

seem like silly things to bet on, but when you're wagering real dollars at scale,

it tends to be incredibly informative to the marketplace. It makes the economy more efficient.

I'm excited about all the innovations that I think are going to come out of sports betting,

especially when it becomes so much more of a mobile application.

Hill: One of the ripple effects that we saw in 2018 in terms of sports betting and the

legalization played out in media. In the subsequent months, pretty much every major network,

both on the regional level and on the national level, started to roll out programming aimed

specifically at betting. Argersinger: Absolutely. You see it all the time now.

Hill: Aaron Bush, what is a stock --

or an industry; you can go broad if you want -- in terms of upside for investors? Let's face it,

it's been a volatile couple of months here. We're looking for some upside.

What do you have? Bush: I'm going to go big and then narrow down.

Software-as-a-service. The past two years have been huge for emerging software companies.

But I do think this is an instance in which winners will keep on winning,

and a lot of these stocks have been beaten down in the recent turmoil, too.

Unlike the consumer-facing innovation,

which is occurring mainly in startups and the massive tech companies,

there are tons of great options to invest in small and mid-cap software companies with lots of room

to multiply. Some of these will turn into the next Oracle or Salesforce. A basket of

three stocks that I have super high conviction in that I think will do well in 2019, definitely

beyond: Twilio, which is a leading communications platform; Alteryx, which is a leading data

blending and analytics platform; and MongoDB, which is a next-gen database services company.

All of these companies are growing super-fast, are dominant in what they do, have very little competition.

At scale, they're going to be producing ridiculous amounts of cash flow.

I'm super excited to see what these companies do, even though they've already been hyped

in the past years. Hill: Also, a fun basket of names.

It's fun to say Twilio. What about you, Matt? Argersinger: I'm going to jump way out

and talk about an entire sector. Real estate has really underperformed recently thanks to,

as you'd expect, higher interest rates. Homebuilders especially have been really hit hard.

But the sector itself is what you want to have some exposure to over the next few years.

Despite what the conventional thinking might be, real estate actually does

quite well in periods of higher interest rates, higher inflation. One safe, cheap way to play it

is to buy the Vanguard Real Estate ETF, ticker VNQ. It pays a nice 4% dividend yield,

gives you a broad exposure to a bunch of publicly traded real estate companies and REITs.

I think it has a real chance of outperforming the S&P over the next few years.

Hill: On the other side of the spectrum, it can be a stock to avoid, or maybe just one

to have on a really short leash. In terms of that category, Aaron, where are you?

Bush: I think the marijuana industry is super interesting, but it was so hyped in 2018,

I think 2019 is going to bring disaster to investors investing for the most part in that industry,

but especially in the companies that were the most hyped, like Canopy Growth,

Tilray, Aurora Cannabis. If you're investing in those, watch out, 2019 is almost definitely

going to be a rough year. Argersinger: It was funny, Aaron and I talked

back in the fall. We both said, watch out. As soon as cannabis gets legalized in Canada,

which was mid-October, you could almost draw a straight line from that point on. That was

the peak of a lot of these stocks. They're down huge since then, even more so than the

market we've seen. It's funny, it was one of the easiest calls I think you could have made.

And it still has more to go. Hill: It was interesting in part because it

wasn't just individual investors who were excited about this. We saw major companies,

consumer brands that everybody knows, investing hundreds of millions,

and in some cases billions of dollars. Argersinger: Coke, Philip Morris. Amazing.

Hill: What do you have on a short leash? Argersinger: You can probably guess.

I'm going to say Facebook needs to be kept on a short leash, if not avoided altogether.

All the problems I mentioned regarding the social networking space... the stock price looks cheap.

You can call it that. If you assume that they're going to continue to grow their

advertising revenue at a similar pace, or even slightly slower pace, yes,

the stock looks very, very compelling. I just think there's going to be a big reset in expectations

across the space. I have big questions about whether Facebook can effectively monetize

Instagram and WhatsApp without damaging user experience. And I'm not even getting into

the leadership questions you have to have right now around Mark Zuckerberg and Sheryl Sandberg.

I just think you can do better elsewhere. Don't try to catch Facebook, even though it's

a snazzy name with now a cheap valuation. Hill: This happens at this time every year:

investors and particularly the business media start to look ahead in terms of private companies

going public. Despite the volatility that we've seen recently, you've got executives

on Wall Street saying, "Actually, that might accelerate plans for private companies to go public."

In 2019, some of the best-known names, Aaron -- Uber, Slack, Airbnb, Lyft.

Is there one that you're either really hoping goes public, or you're just eager to get your

hands on the S-1 filing? Bush: I hope Stripe goes public sooner or later.

It might not IPO this year. They're a payment platform that makes it super easy

for companies to sell things online. Their developer tools are known to be excellent.

They continue to roll out new solutions. The founder and CEO, Patrick Collison, seems to

be a super thoughtful. It wouldn't surprise me if one day, because this market is so big,

buying things online, that Stripe becomes a larger payments company than PayPal.

I think that's super fascinating. Right now, they have a market cap of about $20 billion,

so I would love for them to go public sooner than later, [laughs] before they start hitting

the upper tens of billions in their valuation.  Hill: Do you think they're at the point now

where they're way past the acquisition standpoint? Bush: It would be a big acquisition. I doubt

it would happen, at least from another payments company. I bet they'll go solo public.

Hill: Matty, what are you eager to get your hands on?

Argersinger: You mentioned it, Airbnb. My wife and I have actually been Airbnb hosts

for over a decade now. What you have is essentially the world's largest, most expansive hotel company

that really doesn't own any of its rooms. It's fascinating to me. It has somewhere

on the order of five million listings, 150 million users in close to 200 countries.

It has a profound network effect, maybe actually the strongest in the world. I think we're

going to realize that. I don't know what the market cap is going to be when it becomes public,

but just in terms of room count and customer count, it's bigger than all the major

publicly traded hotel companies combined. Hill: OK, I really wasn't expecting that at the end.

I'm assuming the answer is yes. Do you have a good rating? What kind of rating do you have.

Argersinger: We have almost a five-star rating

across our listings. Hill: Nice! I'm not surprised,

but I'm very pleased for you. Alright, we've got just a couple of minutes left before we wrap up.

We do this every year, reckless predictions. Make them reckless. They don't have to be

about business, although they can be about business. You can go off the board to sports,

pop culture, whatever. Aaron, what do you have?

Bush: Even though the Chinese trade wars and economic slowdowns will continue to generate headlines,

I predict that in 2019, we'll see the largest technology acquisition in which

a Chinese company buys a U.S. company. I don't know if that's Tencent buying one of the big

three video game companies, maybe Alibaba acquires eBay as a way to get into U.S. e-commerce.

Maybe DiDi, which is larger than Uber at their last valuation, acquires Lyft as a way to

get to the U.S. markets and get a partnership with Waymo. I don't know. There are interesting possibilities.

Hill: That would be fascinating! Matty, what about you? Argersinger: I think Warren Buffett's going

to buy an airline. Hill: [laughs] Really?

Argersinger: Berkshire Hathaway already owns major stakes in all the major U.S. airlines.

The industry has changed. Consolidation has made this much more a value creator than a

value destroyer. You have a strong airline like Delta that's actually been assigned an

investment grade credit rating. It's buying back shares and paying a dividend, and the

valuation is very cheap. This is a different industry now. Much like how Buffett viewed

the railroads 10 or 15 years ago, I think he views the same with airlines today.

Hill: That would be maybe the greatest example of someone taking emotion out of investing,

when you think back on how much Buffett used to openly hate the airlines as an industry.

Argersinger: Oh, absolutely! Hill: Alright, Matt Argersinger, Aaron Bush,

guys, thanks for being here! Happy New Year! Coming up: our 2019 preview rolls on with

Ron Gross and Jason Moser. Thanks for being here, gents!

Ron Gross: How are you doing, Chris? Hill: I'm doing well! The 2019 preview rolls on.

Real quick, though. We talked about Apple at the top of the show. Jason, any thoughts

in terms of one of the largest companies in America and where it is right now?

Jason Moser: As Aaron was saying, I'm really surprised that people are surprised by this.

It's not something that I'm all that taken back by. In November, we were talking about

Apple's chip suppliers ratcheting back their guidance, which was more or less implying

that there may be some weakness in iPhone performance like we're seeing. Granted,

they seem to be holding China accountable for most of this. But it all makes total sense.

As iPhones get better, they last longer, you don't have to upgrade as much. They can only

raise prices so far until consumers become a little bit more sensitive. Everybody wants

to just get on Apple's case here and predict that this may be the beginning of the end.

But let's be clear, it's still Apple. They're still selling millions upon millions of devices.

They lost control of the conversation a little bit because they're not going to be announcing

those unit sales anymore. But there are a number of different ways they can win.

It's not going to be just Services. Services will have to be part of it. But when you look at

Services, other devices, the portfolio of wearables, you can't discount the potential

big acquisition at some point or another, either, with that balance sheet. iT's all like just

take a step back here... Gross: I'm all for the take-a-step-back approach.

I think that makes good sense. I'm going to be really curious to see if Warren Buffett

and Berkshire Hathaway are buying stock during this period of weakness. I would

be one of those analysts that would recommend that investors take a position at these levels.

11X-12X forward earnings, there's not a lot of growth built into the stock at this price,

and they've got a lot of ways they can win. Moser: And let's remember, too, we have a

whole generation of smartphone users that haven't bought smartphones yet. There are

going to be plenty of opportunities to get new smartphones in new consumers' hands,

and there's a brand loyalty there that's quite impressive.

Hill: Ron, let's get to the preview. When you think about 2019, what's your biggest

question as an investor? Gross: My biggest question is,

will value investing rise from the dead? As most of us are aware, growth has nicely outperformed

value over the last, let's call it a decade. Not just a few months here and there,

but quite a few years. FAANG stocks are perhaps the most obvious examples of growth stocks

that have led the way. Obviously, we've had an extended bull market. That tends to favor

growth stocks. So, my big question is, do we see a resurgence of interest in stocks

that are considered value? Growth often does underperform in bear markets. If, perhaps,

we are entering a bear market, are we going to see a sustained bear market, then one would

expect value to come back into vogue. But, you know what? We haven't seen it anytime

in recent past. Hill: What about you, Jason?

Moser: We've talked a lot about Disney and their move to over-the-top distribution.

They own part of Hulu, which I think they've done a good job building out, especially with that

live Hulu offering. ESPN+ seems like it's gaining some traction. And now, Disney+ is

going to be their service that launches sometime in 2019. We talked before on the shows,

they really need to make sure they execute there. I do think that's a compelling product.

It's going to take a lot of content away from other streaming partners, namely Netflix. I find it

interesting to see that the shows on Netflix that garner the most views as a percentage

are all shows that are not Netflix shows. I think that's telling. Netflix is still having

to put up a lot of money to get content that people want to see, and Netflix is not the

one producing that content. They still, have a little ways to go in succeeding on that

original content front to justify all of that money that they're spending. I think that

Disney+ is going to re-emphasize the competitive advantage that they have there

in that intellectual property.

I'm excited to see how that product arrives. I'm certain that we will at least

be testing it in our house, if not becoming full-fledged subscribers, unless they really

drop the ball. Hill: Wasn't there a minor freak-out in the

Netflix universe when they said they weren't going to renew the show Friends?

Moser: Yeah. Gross: In my household, for sure.

Moser: That is something that they need to pay attention to. As a percentage of views,

Friends is No. 2 on the list just behind The Office. When you look at that list of

the shows that are garnering the most views on Netflix, it takes you back, not a lot of their

original content is on that list. It just tells you they still have a little ways to go.

Hill: What's a trend you're excited about this year, Ron? Gross: It piggybacks off of what Jason was

just discussing. 5G technology, fifth generation wireless cellular technology, is coming,

and it's coming pretty quickly. It's going to be pretty exciting. It's going to make devices

more capable of accessing the internet, it's going to deliver much faster speed than 4G,

some say 20X-100X faster than 4G. Lots of companies are going to benefit here.

The most common names would be AT&T, Verizon, T-Mobile. But I think Nokia, even Apple will benefit

as people upgrade to 5G-enabled phones. It's going to be a really exciting trend to watch

from an investment perspective, but also from a consumer perspective, because I think we'll all benefit.

Moser: I'm glad you mentioned Apple there.

That's another point with 5G. I think they're going to be a little bit behind others in

getting their devices up to speed. But once that does happen, that's going to be another

catalyst there in the upgrading. For me, I'm excited about podcasts and where

podcasts are heading. Gross: Shameless plug!

Moser: I'm not going to just pat ourselves on the back here too much, but it's worth

noting that you and Mac and our partners here, you had the senses to make some early bets

in this market back in 2010 and 2011. And lo and behold, now, in 2019, we've got a

full-fledged family of podcasts. They're doing very well. We've seen Sirius XM acquire Pandora,

noting in their call that, to their dismay, they passed on podcasts for a while.

They admitted that mistake, and they're going to start putting some resources into podcasts

and building out that environment. I think we're in a day and age now where Netflix

really changed the game for content for people being able to watch what they want, when they want,

and where they want. Now, we're seeing the same thing play out on the audio side.

We're able to give people what they want, where they want it, when they want it.

It's nice to be a part of it. Hill: Let's talk stocks. Ron, whether it's

an industry or a specific stock, what do you think is poised for upside this year?

Gross: An industry I'm looking at, it's a sector/ industry. I'm not ready to call

the big r-word yet, recession. I'm not freaking people out yet.

Hill: You are a little bit, by saying that. Gross: I think it's important to have some

allocation to some defensive stocks in the environment that we may be approaching.

So, when I think of companies in those sectors, I would say some utilities might be a good

bet right here. Some of the discounters, in fact, discount retailers. Costco, Dollar Tree,

Walmart would be some nice stocks, defensive stocks to have as we enter an economy that

might not be as robust as it has been. Hill: What about you, Jason?

Moser: I don't want to time when a recession might hit, because really, that's bad for everybody,

but I do think we are entering a period where banks are going to have some

opportunities to boost their earnings a little bit as interest rates continue to nudge upward.

In particular, I'm looking more at small banks, and one we've talked about before,

Ameris Bancorp. This stock has a tremendous risk-reward scenario playing out here.

The stock is now trading around 15X earnings. They recently announced this merger with

Fidelity Bank in Georgia. It's about a $750 million deal. Given that Ameris is about a $1.5 billion company,

you can see, it means a lot. The market rightly sold the stock off.

There's some skepticism there. That's rolling in a big acquisition. But they're two very similar cultures.

It gives Ameris tremendous exposure to the valuable Atlanta market. It's also

going to help grow that asset and deposit base, particularly in a period where a lot

of these banks are competing for getting those deposit bases. So, to me, this could play

out like the McCormick thing. Remember when McCormick acquired RB Foods? The market thought,

"Whoa, this is a big one to digest here," and they held off for a couple of quarters

to see how things worked out. Lo and behold, it worked out pretty well. The stock recovered nicely.

I think we could be looking at the same thing here with Ameris if they execute

this acquisition well. Hill: Ron, if defensive stocks have you interested,

what's at the other end of the spectrum? What are you avoiding this year?

Gross: Specifically, I have one stock in mind. I come back to it often. It's Fitbit.

I've really never been excited and probably will never be excited about this one.

They entered the smartwatch market in 2018. I give it to them, they've done pretty well.

But this is a formidably competitive market, with the likes of Apple, for one, right there behind them.

You even have some Chinese upstarts that could be a problem, as well. I don't

see Fitbit being the company that is constantly able to innovate, either take market share

or defend market share. I'd be really careful about this one.

Hill: What about you, Jason? Moser: Zillow. I've changed my tone on this

company over the past year. I used to be excited about the potential there. I feel like they've

failed to convince me of the sustainability here. They're yet to become meaningfully profitable at all.

Now, in this most recent quarter, they put in their shareholder letter that

Zillow Group has entered a period of transformational innovation. To me, that's code for,

"We're not going to be profitable any time soon." For a company like this, a company that's

been around for a while in such a big market opportunity as our housing market, they should

not be entering this period. They should be coming out of this period. I think that's

what they were trying to do over these past few years. This instant offers business,

it's not up their alley. Buying homes and renovating them and selling them, it's not scalable.

There are a lot of people out there doing it. I don't know that they have any real advantage there.

Good will now represents essentially half of the total assets on the balance sheet.

It's not a bad company. I'm just disappointed in the way they've executed. They still have

a ways to go before they get to meaningful profitability.

Hill: One of the things that ties these two businesses together, Fitbit and Zillow,

is the word "optionality" has been used in connection to both of these businesses. They were seen as,

"They have options, in terms of where they can go." Optionality is something we

like to see as investors, but Ron, it almost seems like optionality works better if you've

got one dependable cash cow in your portfolio. Gross: You nailed it. Optionality is great

for additional upside. Maybe you can't even see the different options that a company might

have three to five years down the road. But if they don't have that profitable cash flow

producing segment of the company, then you're relying on all of the value of that company

being in the optionality category, and that's just too much risk for me.

Hill: Guys, 2019 has just begun, but The Motley Fool is already looking for summer

interns in investing, editorial, software development, and much more. Come, spend the summer!

Gross: Join us! Hill: Join us here at Fool global headquarters

this summer. Go to careers.fool.com for all the information and to apply to be a summer

intern here. That's careers.fool.com. Happens every year, Jason. There are

a few CEOs who are on the hot seat. We're long-term investors, but let's face it: over the long-term,

if you're not delivering, that means in the short-term, you're on the hot seat. What do you have?

Moser: In 2018, I certainly had Kevin Plank

of Under Armour on the hot seat. He's not off yet. I'm calling him out again.

While we are seeing signs that he is embracing relying more on his team, particularly the CFO and

COO of the company, Frisk and Bergman, when you look at the expectations we've had for

this business over the course of the last several years, as it's been a recommendation

in a number of our services, this has been a phenomenal disappointment. The real disappointing part there is,

they were essentially self-inflicted. They just made some dumb investments for the

sake of growing as opposed to making good strategic decisions and letting the growth

come from making good decisions. I think he's on the right track. We need to

make sure that team stays intact here. If we see that CFO or COO leave, we have a really

big problem. But at this point, with the market seeming like it wants to recover, if we don't

have a recession, this is a company that should be performing a lot better than it is today.

Hill: What about you, Ron? Gross: I think Wells Fargo's CEO, Timothy Sloan,

probably should go. He was probably the wrong choice from the get go, as he's been

at the company during all of the controversies. Having taken over the CEO role in 2016,

he's really not done anything to turn the tide. From an operations perspective, the company's

not really doing very well. From a controversy perspective, as well, things don't seem to

be getting better. I think it's time for some outside blood to come in and right the ship.

Hill: I think back to last year's show. I mentioned that John Flannery, who was CEO

of General Electric at the time, I mentioned that he was certainly a CEO to watch because

I thought he was laying all his cards on the table. I thought, "Boy, this is going to be

a really interesting company to watch." In hindsight, I probably should have said he

was on the hot seat. I didn't think he was on the hot seat! Then he didn't make it to

the end of the year. Gross: That's how it goes!

Hill: As I talked about with Matt Argersinger and Aaron Bush, it's interesting to see not

only the companies being named in the private market as potential IPOs this year, but the

possibility that the recent volatility we've seen might accelerate those IPOs in the first

six months of 2019. Whether it's the S-1 that you're eager to look at, or a company where

you just think, "I want this thing to go public now so I can get a few shares," what's on

your radar, Jason? Moser: One that probably a lot of people

are thinking won't end up by IPO-ing. I hope it does. SpaceX, Elon Musk's rocket company.

They're set to raise $500 million at a $30.5 billion valuation shortly. To me, space is

one of these markets, one of these trends that's going to open up a lot of fascinating

investment opportunities over the course of the next decade and beyond. I think SpaceX

is going to be a part of that. One thing that SpaceX is doing today is this

project called Starlink. Essentially, the idea is looking to build out a constellation

of satellites all over the globe in low orbit that will basically be able to beam high speed

internet connection to every corner of the globe. It seems like he's getting buy-in from

all the regulators. We've seen what he's been able to do here in the rocket launches that

have taken place thus far. I think this is a fascinating company.

It's going to offer a lot of opportunities. If we do get a chance to see it go public,

I more than likely would want to own a few shares just to be a part of it. But, I'd really want to read that S-1.

Hill: Do you think Tesla shareholders are

eager for the prospect of Elon Musk at the helm of yet another public company?

Moser: Maybe we save that for another show. [laughs]

Hill: Ron, what about you? Gross: A favorite company in my household

is fast casual Mediterranean restaurant Cava. They recently acquired publicly traded Zoës Kitchen.

I'll give them a little time to digest that acquisition, decide what they want to

do with all the Zoës locations. But then, let's take the whole darn thing public.

Some great capital that they can use for growth to take the world by storm and expand the concept.

Hill: Have they given any more color on what

they plan to do with those locations? I remember, we talked about that acquisition on this show.

The only thing that surprised me was the fact that they seem like, "No, we're not necessarily

going to turn these all into Cavas." I think our general reaction was, why not?

Gross: I've seen more along the lines of making some menu changes, changes to the way

the kitchen operates to be more efficient and have offerings that are more appealing

to the consumer. Hill: Alright, just a couple of minutes left.

Reckless predictions for 2019. What do you have, Jason?

Moser: I was thinking about going with the Red Sox repeating as World Series champions.

Then I thought about it, that's not that far-fetched, really. I'm calling it, they're going to repeat.

That's not my reckless prediction.  I'll go with a more business-related story here.

I was talking earlier about the potential acquisitions that Apple could be looking at here.

What would stop them from wanting to acquire Square. You want to look at expanding

your business and becoming a little bit more of an integral part of the commerce scene here,

not only domestically, but globally. I think Square and Apple have a lot in common.

They're both in the business of developing sleek hardware that people like to use, generating

some pretty strong brand loyalty there. Then, we know, of course, the payments space is

one that's growing very quickly. I'm not saying it'll happen, but it's certainly

an acquisition that Apple would be capable of executing. Maybe it will happen.

Hill: Ron? Gross: I went a little off the rails here.

There's going to be more definitive signs of previous life discovered on Mars in 2019.

That's going to build off of the work done by the Mars Curiosity Rover that, earlier

in 2018, found some organic molecules. We'll figure out where those actually came from

and build on that. There aren't going to be any signs of actual Martians running around

Hill: Or will there? Gross: -- but I think we're going

to see signs of some previous life.

Moser: Alright, reckless prediction No. 2: Ron Gross and Jason Moser will be heading up

the new Motley Fool Space Investing service to launch either late 2019 or 2020.

Gross: [laughs] Sell that short. Hill: I'm just going to say that regardless

of where free agent Bryce Harper ends up, the Washington Nationals are going to the World Series.

Moser: Wow! That is reckless!

Gross: I'll take that bet. Hill: Ron Gross, Jason Moser, guys,

thanks for being here! That's going to do it for this week's edition of Motley Fool Money.

Our engineer is Dan Boyd. Producer Mac Greer on a well-deserved vacation this week.

I'm Chris Hill. Thanks for listening! We'll see you next week!

For more infomation >> 2019 Stock Market Outlook: Stocks to Watch, Trends, & Upcoming IPOs - Duration: 37:43.

-------------------------------------------

The Top Healthcare Stocks of 2018: Can They Continue in 2019? - Duration: 28:04.

Shannon Jones: Welcome to Industry Focus, the show that dives into a different sector

of the stock market every single day. Today is Wednesday, January 2nd, the first Wednesday

of the new year here in 2019. I'm your host, Shannon Jones. I am joined in the studio via Skype

by healthcare specialist guru, all around awesome guy, Todd Campbell. Todd, Happy New Year!

Todd Campbell: Happy New Year to you, too!

I missed you the last couple of weeks! Jones: I missed you too! Glad to be back

in the studio. More importantly, I'm glad because today, we actually get to look back

at 2018 and talk about the top performing stocks of 2018. I don't know about you, Todd,

many of these surprised me when I went and looked at the returns from 2018.

Campbell: I bet a lot of people, after the fourth quarter's dismal performance, are pretty

excited to flip that calendar. Anybody still have a calendar on the wall? I don't know.

Flip that calendar and see 2019. Obviously, a tough end to the year. But people who owned

these stocks are probably smiling pretty broadly comparing their returns against the S&P,

that's for sure. Jones: Speaking of the S&P, looks it was

down about 6% in 2018, about 4% if you include dividends. Then as you look at biotech and biopharma,

the XBI and IBB were also down double digits in 2018. All in all, not a great 2018.

But like you said, Todd, there were some high flyers. Let's start off with the first one.

The first stock is a stock that was actually

up over 1,400%. Campbell: What?!

Jones: 1,400% in 2018. It started off the year with a market cap right around

$26 million, ended the year with a market cap right about $2 billion. Todd, if you would have

told me at the beginning of 2018 that the stock with returns of 1,400% would have

been a diabetes stock, I would have said you're crazy and to put down the cannabis. [laughs]

Campbell: Tandem Diabetes, up nearly 1,500% in the year, and all tied to one really game

changing development that happened over the summer. To give our listeners a little bit

background here, Tandem Diabetes makes insulin pumps. Insulin pumps are increasingly being

used by people with type one diabetes who are unable to produce their own insulin as

a way of more efficiently delivering insulin to their body, rather than having to continuously

be injecting themselves with that insulin.  It's a very competitive marketplace.

There's other players out there. Insulet is a big player there. Medtronic is a big player there.

Up until 2018, Johnson & Johnson's Animas was a big player there. But there were some

changes over the course of 2018 that allowed this company to shine and jump-started optimism

among investors that it's going to jump to the front of the line in terms of sales and market share.

Jones: It really came down to this technology,

the launch of their t:slim X2 with what's called the Basal-IQ technology that's integrated

with Dexcom's G6 technology. In particular, this Basal-IQ technology, now gives the patient

much more convenience and more control because now, this Basal-IQ technology can actually

predict and respond to what's happening with the patient.

Campbell: In the past, you still had to monitor yourself for your insulin levels,

program the dose in for your pump. This automates that. Essentially, what it's done is, it pairs the pump up with,

like you said, Dexcom -- Dexcom was no slouch, either. It was one of the top

performers last year. This device pairs the pump with Dexcom's continuous glucose monitor

and an algorithm. Using all three of those things together, it basically says, yeah,

you should have more insulin, here we go, and it automatically gives you some insulin back.

That's important because so many diabetes

patients spend a large portion of their day outside of the desired blood sugar range.

Of course, that can contribute to the progression of the disease

and all sorts of other life-threatening complications

later on down the road. Jones: Absolutely. One of the things when

you look at Tandem, not only are they innovating with the Basal-IQ technology, but if you look

at their pipeline, they've got a number of different innovative approaches that are really impressive.

They've got a hybrid closed loop system that they are currently in development

with a startup called TypeZero Technologies, actually a startup that was based out of research

from UVA. They're working to build out this hybrid closed loop system. That could launch

in 2020, maybe 2021. They've also got the t:sport insulin delivery system. This is basically

a next generation hardware platform. That looks it could also launch in 2020, 2021.

Also, they're increasingly pushing the needle when it comes to remote connectivity.

You see Bluetooth being integrated with a lot of these insulin pump systems, which makes

it all the more convenient and gives the patient the ability to remotely control their insulin pumps.

All in all, you've got a company that is delivering

on innovation and also has a pretty impressive pipeline to boot.

Campbell: We have a pretty short window of insight into just how much the launch of this

insulin delivery system in 2018 is going to move the needle on sales. They did report

the third quarter results. Those were pretty impressive. Sales were up 71% year over year

to $46 million. That's great. They upped their guidance for the full year in October to revenue

of between $160 million and $165 million. That was up from prior guidance of up to $158 million.

Always good to see that kind of optimism for the company.

You mentioned the new products that are coming out in the 2020 timeframe. That'll be important.

There are other automated insulin delivery systems that are in development.

Medtronic actually was the first one to launch one. They have one out there, but it's not as convenient

and easy to use as Tandem's. Insulet has one in development. Eli Lilly's got one in development

as well. Those could pose a competitive threat to Tandem around that same 2020 timeframe.

Johnson & Johnson got out of the business. That's created more of an opportunity, addressable market.

That's provided a tailwind for the company. I suppose most investors are looking

at it and saying, "Wow, up 1,480% in 2018. Can this possibly have more room to run in 2019?"

Jones: I generally think it does.

Another reason, in addition to their product line, is the fact that they are also expanding internationally.

According to the International Diabetes Federation, globally, you've got about 425 million people

diagnosed with diabetes, of which about 10% have type one diabetes. What you saw in 2018

with Tandem is they were starting to push into international markets. These include

places like Australia, Italy, South Africa, the U.K., New Zealand. Canada also came on board

in the fall of 2018.  All in all, with the product pipeline plus

this international expansion, which I really think they're still very much in the early

innings of, again, you'll have to be mindful of the competition like with Medtronic's MiniMed system,

but I do think that this could continue to go high. Maybe not as high as 1,400% in 2019,

but I still think it's got plenty of room to grow.

Campbell: It's a huge market, 1.25 million people with type one diabetes here in the U.S. alone,

and certainly, not everyone with type one is using pumps. There's still more

room to grow for the pump makers. I do wonder a little bit about valuation.

The market cap has grown pretty remarkably. Even with that upped guidance for sales of

$165 million this year, that's still trading at a pretty good multiple to sales.

But, I do agree with you that there's a lot of running room. Now that the company has this on its

balance sheet, in better shape, it got rid of its debt last year, as well, I think there's

some opportunity here. It's definitely a stock to watch in 2019.

Jones: Absolutely. Let's shift gears, talk about the second stock. This one wasn't as

much of a surprise when it comes to the returns. It did generate a tremendous amount of investor

attention and even media attention. This was one of the darlings of 2018, a company called Amarin,

ticker AMRN. The stock was up about 240% in 2018. I think it's currently sitting

at around $13 a share. It did go as high as $23 a share before the market carnage that

happened in November and December. Todd, in looking at this company, not surprised

to see it as one of the top performers. But, looking back at 2018, definitely surprised

that it was the fish oil pill that really led this company up, up, and away.

Campbell: A lot of people have been waiting on this company to deliver cardiovascular

outcomes results that could prove that lowering triglycerides by using Vascepa, which is its

purified fish oil, did reduce major cardiovascular events like heart attacks and strokes and the like.

People just weren't convinced up until now that using this approach could actually

move the needle for outcomes for patients. I think it was either September or October,

the company rolled out the results from its multi-year, I think a six-year study.

And sure enough, they found that if you add Vascepa to statin therapy in people who are already

taking statins, it provided an incremental additional 25% reduction in the risk of these

major cardiovascular events. That includes a 20% reduction in death, a 31% reduction

in the risk of heart attack, and a 28% reduction in stroke.

That's impressive, and it's important. Cardiovascular disease claims a lot of lives every year.

There's a big need for new treatment approaches that can help these patients avoid suffering

these events. With statins alone, it reduces it by about 25-35%, depending on the therapy

or the intervention that's being done. So, there's still a 65% room for improvement there.

Now, potentially, the use of Vascepa alongside statins, much larger addressable market opportunity

for Amarin, and theoretically puts it on the path to have a blockbuster drug,

assuming approvals go its way, as soon as the end of 2019.

Jones: Absolutely. It should be noted with Vascepa, it's already on the market,

this would be a label expansion for them. Right now, Vascepa is already approved to treat

severe patients that have triglyceride levels above 500 milliliters per deciliter, I believe

is what it is. It's already on the market. As you mentioned, this does greatly expand

the addressable market. Of course, as many healthcare investors will know, we'll start

to see sales ramp up, but you're already seeing that even as we await approval. That's because

doctors can prescribe these drugs off-label. You're starting to see prescriptions already

to ramp up. You'll see even more heading into 2019. Assuming that it does get approved,

you should see a nice surge there. All in all, this was a company that for 2018,

all eyes are on this data. Everybody was waiting on this cardiovascular data. They delivered

on this data. This is a company that honestly was about to shelve this product years ago,

almost didn't make it to market. I do need to give credit where credit is due. The management

team didn't shelve this one. They did go back, look at the data, start to look at subgroups

and find where this drug actually did work. It'll be really interesting to see this coupled

with those statin therapies. Campbell: One of the most exciting earnings reports

for me to watch is going to be the fourth quarter results for this company.

I want to see whether or not, ahead of this approval but following the data, doctors are

starting to prescribe this off-label and driving sales higher. The company has big plans.

They were spending around $50 million on R&D because of the study that is now ended. They're going

to move that money over now to hiring sales people. They're tripling their sales force.

If they get approval, they'll kick off a direct-to-consumer marketing campaign. They're really going to

try and get this out in front of everybody.  It's not an expensive drug like some of these

other drugs we've talked about on the show like PCSK9 inhibitors, those kinds of things

used in this indication. Theoretically, you could gain pretty widespread use. If you look

at some of the best sellers in history, they've been the statin drugs. Just look at Lipitor,

$12 billion in peak annual sales at its height. Jones: Another really interesting thing to

watch in 2019 is to see if big pharma actually comes up, pulls alongside, whether it be a

partnership deal or if Amarin just gets bought out all in all. They'll be launching hopefully

in the EU as well. They'll definitely at least need a partner there. I think that'll be a

big storyline to watch, as well. Campbell: Yeah, they want to partner over

in Europe. It'll be interesting to see if we get some news out of them in the first

six months or whatever. They have not filed. They're debating. They're trying to figure out,

should we file and then get approval and then try to partner up? What will that

mean for economics? Or should we do it the other way around? That's going to be something

to keep an eye on. People are also going to want to keep an eye on a study of another

drug that works similarly. AstraZeneca has a drug called Epanova. That's also a fish

oil pill that's in late stage studies. Data could be coming from them in 2020.

As Amarin has said in the past when asked about that drug, the difference is that AstraZeneca's drug

does include another type of fish oil called DHA. Historically, in trials, DHA has

increased bad cholesterol levels. That's why historically, fish oil studies have not panned out.

This is the first one that has panned out, because Vascepa is a purified EPA fish oil.

It doesn't have DHA. Jones: Yeah. Their management team has really

been driving that point home very hard, that this is a purified form. A lot to look forward

to in 2019 with Amarin and also with AstraZeneca. We've talked about two smaller up-and-coming stocks.

Let's talk about some of the larger ones that have also generated some impressive

returns in 2018. The first is a company called Abiomed. Todd, you and I talked a little bit before

this show about how 2018 was the year of medical devices and med tech. This stock is no different.

Ticker symbol is ABMD if you want to check it out. Todd, this is another one that generated

some really impressive returns. Campbell: Absolutely crushed the S&P return.

Up 73.4% in 2018, making it one of the top performing stocks within the index this past year.

One of the interesting things, you were talking about medical devices, a lot of these

top stocks in 2018 have a common thread.

They address, in one way or another, cardiovascular disease.

Abiomed makes heart pumps that can be used temporarily in patients who have suffered,

say, a heart attack, some sort of a cardiovascular event, to basically bridge them as they either

undergo surgery to repair their heart, or to help them rest and their heart to heal

to avoid having to have, say, a heart transplant. Jones: Their technology is under the Impella brand.

What's really interesting is, it sounds they don't even have a ton of direct competition.

As I was reading more and more about their different technologies, they're quietly,

in many ways, starting to change the treatment paradigm for many of these massive heart conditions,

heart failure, heart attacks, you name it. They're going after nearly every single indication

with little to no direct competition as it stands, yet.

Campbell: There's been not a tremendous amount of advance in survival rates for people who

suffer these cardiac events over the last 20 years, until now. We have Abiomed and its

temporary heart pumps. One of the things that they talked a lot about in 2018 was, if you

employ best practices using these pumps, you can get survival rates to go from 50%, where

they've tracked historically, to 75% or better. That's just remarkable. It can also be pretty

cost saving. These are expensive procedures. Having cardiac failure, needing a heart transplant,

or open-heart surgery, these are expensive, costly things. If you can have a product like

the Impella, that allows a patient to recover more quickly and to go home with their own heart...

it's remarkable. It's interesting, too, I was just going through

their conference call ahead of the show to get a feel for what we're looking at here.

There's still a lot of running room for this company. They think that their devices could

be theoretically, over time, used in hundreds of thousands of patients, which would, obviously,

send their sales much, much higher.  They've got a great balance sheet, plenty of cash,

debt free. Like other companies we've talked about, they're increasing the revenue

guidance because of approvals in 2018 that have expanded their addressable market.

There's a lot of reasons to like this company. Jones: Additionally, they're also looking

internationally. For instance, in Japan, there's a huge market opportunity. It's the second

largest medical device market in the world. 150,000 patients seeking treatment for the

indications which their products are intended to treat, which is amazing. Right now,

their current product lineup, they've got a total addressable market of about 220,000 patients

with their pipeline. That could now add another 300,000 patients. They've got two really large

indications that they're going after, targeting some more serious heart conditions, too.

As a matter of fact, for our listeners, we actually had one of our Foolish colleagues,

Brian Feroldi, sat down and did an interview with the CEO in August 2018 to talk about

the market opportunities and competitive threats. If you're interested, google The Motley Fool

sits down with Abiomed to check it out. Highly recommend it because he really gets down into

what will be important for 2019 and beyond. Todd, all in all, I think there's a massive

runway for this company. You'll hear a lot more about it heading into 2019.

Campbell: I just double-checked and they're only 10% penetrated into the market,

according to management, to those numbers you gave of the addressable market.

Jones: Huge addressable market there. A very interesting stock to watch.

Let's round out the show by talking about the largest of all of these stocks we've talked

about so far, and that is the biopharma behemoth Merck, ticker MRK. The stock was up over 35%

in 2018, which is really quite impressive when you consider that Merck is a company

with a $195 billion market cap. What's even more impressive is that much of this stock's attention,

much of the gains, have come down to one key drug that is the gift that literally

keeps on giving. It's the checkpoint inhibitor Keytruda.

Campbell: Keytruda is so important to this company. You know what's interesting,

looking at the companies that we've talked about on today's show, Merck is the only one that's

a single digit year over year grower. There may be multiple things going on.

Keytruda is absolutely what was driving the car in 2018 for its success. We'll get into

those numbers in a second. Maybe also, investors were getting a little nervous and wanted to

get a little bit more protection. As we've talked about in the past on the show, pharmaceuticals,

especially cancer drugs, not really something that is tied to economic activity.

If you need the drug, you need the drug. A lot of times, people tend to go in a flight to safety

to some of these pharmaceuticals. We also saw one of the top S&P performers in the year

was Eli Lilly. Over here at Merck, Keytruda has become

the most widely used of these checkpoint inhibitors. What these checkpoint inhibitors do is,

they allow the immune system to find the cancer cells, because sometimes cancer cells will

hijack a mechanism called PD-1 that allows them to tell the immune system, "Hey, we're

just normal cells! Don't attack us!" Well, as more and more trials have been conducted

that have proved that Keytruda is effective and safe, it's getting more and more widely used.

In the first nine months of 2018, this drug alone did $5 billion in revenue.

In the first nine months. It's just remarkable. That was up almost double in the first nine months,

including an 80% year over year jump in the third quarter.

Jones: That's not at all shocking. When you look at Keytruda right now, it's already approved

for use in 12 different indications across eight different tumor types here in the

United States. That's just the United States. You can see, Keytruda certainly has a very long

growth runway ahead of it. Not only that, Keytruda is being studied in

more than 30 types of cancer. 850 different studies around the world, 500 of which are

these combination studies, which I think you'll hear more about in 2019, as we did in 2018,

to see how these checkpoint inhibitors like Keytruda or Bristol's Opdivo work in combination

with these other immuno oncology products. Certainly, a lot to be had moving forward.

But, certainly, Keytruda has been the growth story of the year for Merck.

Campbell: 2019, things to watch. They have five applications that are awaiting a decision

from the FDA that could, again, expand even further the addressable market. They have

a number of other readings that are coming out from trials they're conducting that are going

to come out over the course of the next 18 months. You'll want to stay tuned for those.

Overall, peak sales estimates for this drug, I've seen as high as $12 billion or something

like that by 2024. Even though it's on track to do $7 billion in sales this year, you could

still see this go another 50% higher from there. That's more than offsetting declining

sales from Zetia after losing its patent production. That was their multi-blockbuster drug to help

reduce bad cholesterol levels. Once that lost patent protection, people were worried,

what are they going to do to be able to offset those sales? Obviously, Keytruda is doing that.

That's why you've got this company that's still putting up relatively solid growth for

a company its size in 2018. The other thing that we should remind our

investors is that it's a dividend paying stock. That's always nice. Because their balance

sheet is so good and Keytruda has been so successful, they've been able to increase

their buyback authorization and boost their dividend. Those are tailwinds, as well.

Jones: Yeah, absolutely. A lot to like here with Merck. Really, a lot to like with all

four of these companies heading into 2019. I must say, coming out of 2018 with the market

being down and with biotech stocks getting hammered, it's so good, so refreshing to see

companies like these four companies that are not only innovating, making money, but also,

more importantly, they're improving patient outcomes and the quality of patient care.

With so many negative headlines, it's so good to see these companies innovating where it

matters and winning where it matters most. Campbell: The one thing I will do as we wrap

up the show, tempering a little bit of enthusiasm here, I did go back and look at the top performers

of 2017 to see OK, the top 10 performers in the S&P in 2017, how many of those repeated in 2018?

Only four of them did. [laughs] So, just because you had a very strong 2018 does

not guarantee you'll have a strong 2019. Bear that in mind when you're considering these stocks.

But, it's fascinating oftentimes to look at

these names and see what people are doing. Certainly, names worth adding to watchlists.

Jones: Absolutely! Wise, wise words from Todd Campbell here. That's it for this week's show.

We want to thank our listeners so much for tuning in. As always, people on the program

may have interest in the stocks they talk about, and The Motley Fool may have formal

recommendations for or against, so don't buy or sell stocks based solely on what you hear.

This show is produced by Austin Morgan. For Todd Campbell, I'm Shannon Jones.

Thanks for listening and Fool on!

For more infomation >> The Top Healthcare Stocks of 2018: Can They Continue in 2019? - Duration: 28:04.

-------------------------------------------

Dumbbell Bodyweight Blaster Workout | Jay Maryniak - Duration: 6:00.

What's up? Performix athlete Jay

Maryniak here,

and I'm about to take you guys

through my Dumbbell Bodyweight

Blaster.

The goal of this workout is

we're going to keep that heart

rate up. We're going to be

building strength and burning

fat.

Alright, so this workout is

structured a little bit

differently.

We're going to be working for

40 seconds,

resting for 20, and then resting

for a minute and 20 in between

sets. This workout is going to

take about 30 minutes.

So if you guys are ready, let's

get after it.

Alright, we're kicking things

off with Romanian Deadlifts.

A little bit different than a

normal deadlift here because

we're going to be going for a

tempo of 4,

2, and 1.

So, we're going four seconds

down,

two second pause in the bottom,

and then one second coming up.

Key point here guys is keeping

that spine neutral.

I see way too many people,

at the bottom of that deadlift,

cranking their neck back,

keeping it in full extension

looking up.

Make sure you guys are looking

down. Keep that spine

completely neutral through the

up phase and through the down

phase.

All right, now we're moving on

to the Dumbbell Push-up

Pull-through.

That dumbbell is going to be

about at your rib cage.

We dropped down to that push-up,

extend to the top.

We reach across the body.

Really try to keep those hips

locked in.

Alright, don't sway back and

forth.

Pull that dumbbell through and

make sure your feet are about

shoulder width.

Down back into that push-up,

alternating sides.

So this movement has a major

core focus because what we're

doing is we're fighting against

the rotation as we pull

through, which really forces us

to lock that core in and really

work those abs and core.

Alright, so we're dropping down

to the floor. We got our Hollow

Body Crunch.

We extend the legs out,

we're pointing the toes,

we're keeping our low back

pinned to the floor,

arms up overhead.

What we're going to do is draw

those knees in while we draw

our arms down.

Contract the abs and core,

and then extend back to our

start position.

So we really want to try to

keep the legs off the ground

and keep that tension the

entire time.

If you absolutely have to rest,

that's okay.

Get right back up and keep

moving.

Alright, we're moving on to the

Dumbbell Thruster to Reverse

Lunge.

This one's going to be rough,

guys. Really focus on

that front rack position.

We're going to start off,

we're going to move down to

that squat.

Keeping the dumbbells nice and

tight to the body.

We're going to thrust out of

the bottom to an overhead

press.

Bringing it back down to that

front rack position and then

stepping back into the reverse

lunge on each leg.

Key things to focus on here:

After that thruster,

you might be a little bit off

balance. So really make sure

you get set,

step back,

alright stay nice and tight,

core tight and drive up.

So you should really be feeling

this movement in the quads,

glutes, and hamstrings.

There's going to be a whole lot

of suck in this movement,

so really stay focused,

keep pushing through.

Moving on to the Broad Jump to

High-knees. Now the heart

rate is already going to be up

nice and high after that thrust

reverse lunge.

So we really got to take a deep

breath and get focused.

Feet under the hips.

We draw those arms back.

Big jump forward.

Landing with the soft knee and

then we fire those knees going

backwards. I really want you to

focus on arms and legs

going at the same time,

fast going back.

Moving on to the Dumbbell

Single-arm Bent-over Row.

So the heart rate is already

going to be really high here.

I really want you guys to focus

on technique.

So really stay focused.

Keep breathing.

What we're going to do,

bent-over row position. Make

sure the back is nice and flat,

core is tight.

We're going to row, two second

pause at the top of the rep,

extend back down, and then hit

the other side.

There's going to be a lot of

time under tension here.

So you're really going to feel

this in your hamstrings, your

glutes just holding yourself in

this position.

But then we bring in the single

arm row with the ISO which is

really going to fire those

posterior delts and lats.

So now we're bringing it back

down to the floor, going to our

Hollow Body Pullover.

So we're going to get set up

into our hollow body position

which we already worked at the

beginning of the workout.

We're going to grab our

dumbbell, we're going to put it

up into that bench press

position.

Right, keeping that low back

pinned to the floor,

toes pointed. We're going to

reach that dumbbell overhead.

We're going to then bring it

back to that starting position.

Really make sure you keep those

toes pointed and keep those

legs raised.

We do not want to rest.

If you absolutely have to,

touch down real quick, pop back

up. We really want to keep that

time under tension here.

Really keep those abs and core

working.

So now if this movement is too

advanced with the weight,

there's a couple of different

ways to modify. You can do

without the weight and you can

also bend the knees.

Alright, the Burpee Tuck Jump.

It's the final exercise in the

circuit. Hands under the

shoulders. You're going to kick

those feet out.

Jump the feet in.

Big tuck jump bringing those

knees up.

Let's bring the intensity.

You're going to get a nice

solid rest after this.

Let's go.

Key points here, really make

sure a nice soft landing on

those jumps. Do not slam down

or have your legs extended when

you land.

Bent knees,

soft landing, receive that

properly.

Really make sure on that tuck

jump you're bringing those knees

as high as you possibly can

here. We're working legs.

We're working core.

Let's go.

You should be feeling it,

back,

biceps, chest,

core,

legs,

full-body.

I recommend that you do this

workout twice to maybe three

times a week.

The full breakdown of this

workout is detailed below here

at bodybuilding.com.

If you have any questions about

this workout,

find me on Instagram or

Facebook at jtm_fit.

For more free videos and

articles from Performix

athletes like me,

come back to bodybuilding.com.

For more infomation >> Dumbbell Bodyweight Blaster Workout | Jay Maryniak - Duration: 6:00.

-------------------------------------------

Deadly Class, nueva serie con actores latinos | Noticias Telemundo - Duration: 4:59.

For more infomation >> Deadly Class, nueva serie con actores latinos | Noticias Telemundo - Duration: 4:59.

-------------------------------------------

Arte en los autobuses salvadoreños | Noticias Telemundo - Duration: 2:12.

For more infomation >> Arte en los autobuses salvadoreños | Noticias Telemundo - Duration: 2:12.

-------------------------------------------

What Should Investors Think of Apple's Disappointing Guidance? - Duration: 23:30.

Chris Hill: It's Thursday, January 3rd. Welcome to MarketFoolery! I'm Chris Hill.

Joining me in studio, from MFAM Funds, he's been out for a while but he's back now, it's Bill Barker.

Thanks for being here! Bill Barker: Thanks for inviting me back!

Hill: We'll get to why you've been out in a little while. The way you just said that,

it sounded like, "Oh, I would have come back sooner, but you didn't invite me." No, you were

out for a while. We'll get to that. Barker: I wasn't invited. Maybe I would have

come in. Who knows? [laughs] Hill: Yesterday afternoon, around 02:30 PM,

you and I were on Slack going back and forth. You wrote something to the effect of,

"What are we going to talk about on Thursday? There's not really any news. Let's figure out what

we can talk about." I think the news fairy overheard you, because there's a $74 billion

deal in the biopharma industry, and that's not the lead story today.

Barker: No. Distant second. Hill: Distant second. That's because Tim Cook,

CEO of Apple, sent a letter to shareholders. It went something like this. "Dear Apple shareholders,

remember back in November when we forecast that our first quarter revenue was going to

be somewhere in the neighborhood of $89-93 billion? How would you feel about $84 billion instead?"

Shares of Apple are down 9% today. Barker: Yeah. The attempt to spice that bad

news up with, "By the way, we're going to have an all-time record for earnings per share,"

didn't seem to work. I don't think there's any surprise here, when you lower the revenue

guidance as much as they did, especially for Apple, which is well known for providing very

cautious guidance. Largely accused of sandbagging on guidance for the last decade, at least.

So, when they say $89-93 billion, the usual response is, "Let's start with $93 billion

and add a little more on." This is talking about the Wall Street analyst community. Normally,

for many companies, you take the midpoint of the guidance as, "We've really evaluated this,

and somehow we've come up with the exact midpoint of the guidance that has been handed to us."

Hill: $91 billion.

Barker: Though, with Apple, you're going to be above that, because history has shown you

that that's what's likely to come in closer to the reality. And this time, no such luck.

Hill: Apple is going to report their first quarter earnings somewhere in the neighborhood

of February 7th. We've got a little over a month to go. Cook gave an interview with CNBC

where he talked about traffic being down in their stores. He talked about China.

A lot of it was about China. He said he hadn't seen the December numbers yet, but clearly,

the indication was that they were bad enough that they're lowering guidance very early in January.

In that interview, he seemed to spell out two basic challenges that Apple is dealing with.

One is of their own making, one is not of their own making. The not of their own

making is the macroeconomic environment, the slowing of the economy in China, the trade

war having an effect, that sort of thing. Of their own making is the fact that they're

selling a $1,000 phone and trying to get a lot of people to buy it at the same point

in time when -- and he made reference to this in the CNBC interview, he talked about the

battery replacement program that they did last fall, how they dramatically lowered the

price of the batteries, I think it was down to $29. You had a lot of people taking advantage

of that. And because of that, they said, "I don't need to upgrade my phone.

Why would I go out and upgrade from an iPhone 6 to a 7, or a 7 to an 8, when the battery was the

problem and now it's fixed?" Barker: I think that in a lazy world,

you would refer to this as a perfect storm. I've always considered that to be among the laziest

evaluations of what's going on, is to find three factors and combine them and pretend

that somehow, that's a unique circumstance. But you've got China generally slowing down.

You've got China-U.S. specifically being an issue. And Apple, in many ways, being a poster boy

for the U.S. And then, you've got Apple's specific choices, as you mentioned, being

largely around the pricing of their product. They make better and better products,

but there appears to be a limit to which large numbers, or at least sufficiently large numbers,

of people will go, in terms of buying a new phone when the one that they've already got

is already awfully good. And Apple's history of being able to encourage people to upgrade

their phones again and again and again has taken at the very least an interruption.

Tim Cook is talking about the various ways that they can mask the real cost of the phone

by getting people to pay in installments. Of course, it was masked for a long time,

in terms of what you would pay, because the service carrier was picking up part of the

real cost. You were paying for that in your contract with AT&T or whoever. That's largely

been interrupted. People are seeing the full cost of the phone and are hesitating.

Hill: This is a stock that, as I mentioned, down about 9% today. Down nearly 40%

since last fall. They have all that cash on the balance sheet. When you look at Apple priced

as it is today, do you look at it as a buying opportunity? Or do you think this thing has

further to fall? Because the CEO himself said yesterday, "I haven't seen the December numbers."

It's not out of the realm of possibility that the December numbers are actually worse

than he and his executive team are imagining. Barker: To be wishy-washy, I would say both.

I think it's got further to fall in the short-term. That said, given the net cash, which I think

the letter refers to as $130 million right now, that's about $30 a share --

Hill: $130 million? Or $130 billion? Barker: $130 billion.

Hill: That's a big difference.

Three more zeroes, anyway. Barker: Well, some would say.

On a day like today, who can tell? So, $130 billion.

That's about $30 a share on the share price. They're about $4.7 billion, so I'm rounding up.

It's not quite $30 per share. That out of, call it $144 right now that Apple's going for,

something like that, you're spending about $114 net of the cash. It's got about

$11 a share in earnings. So, about 10X the earnings power of the company. What are they going

to do with all that cash? They're going to keep buying back their shares, which they've

been doing pretty aggressively over the last six years. Over the last six years, earnings

per share have grown 11% per year for Apple. That's off of a peak, six years ago was an

interim peak. The actual net income has grown about 6%. They've not quite doubled

their earnings per share growth by buying back what is closing in on two billion shares.

They bought back about 25-30% of the company over the last six years. They can continue to do that,

buy back maybe 5% a year of the company, with just cash on hand and the cash flow that

they're getting, and continue to pay the dividend, which is yielding about 2%.

You may see an interruption in their growth. Of course, the letter refers to all the other

areas other than the iPhone as doing pretty well. They refer to, I want to say either

19% or 29% growth in the other areas of the company. That's not bad. The diversification

outside of the phone is a net underneath things. But iPhone is still certainly the biggest part.

Hill: Absolutely. The Services business has

been steadily growing. It's now, I would say, more than meaningful revenue. But, as you said,

this is all about the iPhone. As long as the iPhone is not flying off the shelves,

we're going to see days like this. Barker: Let me get the number right,

it is in the letter that "revenue outside of our iPhone business grew by almost 19% year over year,"

which is pretty good. It's a very large company. The non-iPhone part of Apple,

which is the HomePods and the Macs and iPads --

Hill: The Watch.

Barker: -- the Watch, the Services. Services were $10.8 billion for the quarter.

There's a lot of very large business going on outside the iPhone.

But the iPhone is the biggest chunk, certainly. Hill: The deal of the day is Celgene and Bristol

Myers. Bristol Myers, one of the big pharma companies, buying Celgene, one of the big

biotech companies, to the tune of $74 billion. Celgene shareholders -- I believe you are one?

Barker: Yes, I am. Full disclosure.

Hill: Here's what you're going to get in this deal. You're going to get one share of Bristol Myers stock.

You're also going to get $50 in cash for every share of Celgene.

How are you feeling? Barker: I guess I feel better than I did

before the day it started, in terms of Celgene, which has had a rough go of it. Bristol Myers

is selling off quite a bit. I and other shareholders will be getting that share of Bristol Myers,

if we want to keep it, as well as the $50 in cash if the deal goes through. I don't

have any reason to believe that it won't. But time will tell. Some things do fall apart.

Hill: It's expected to close in the third quarter.

Barker: Yeah, and we're just at the beginning of the first quarter. There's plenty of time

for events to supersede. Hill: As they say in sports,

there's plenty of time to blow this lead. Barker: Well, it's not that much of a lead.

Bristol Myers is down quite a bit. I guess the question for shareholders is, if the deal

goes through, do you want to hold on to this share of Bristol Myers that you're going to

get in replacement for your share of Celgene? The market doesn't like what Bristol Myers

has done seemingly, which is understandable from the traditional metric, which is an acquiring

company's shares go down and the acquired company's shares go up. That's what's happening.

For the last couple of years, you saw that pattern broken a lot, where the acquirer was

going up no matter what. Everybody liked everything in the stock market. But we're seeing,

first of all, a day in which there's a certain amount of pessimism in the market. I think that Bristol Myers

is pretty interesting at the price that it's going for right now.

Hill: Bristol Myers, to put some numbers around it, the stock is down about 12% today

on this news. Celgene up 25%. I was talking with Shannon Jones, one of the hosts of our

Industry Focus podcast. She hosts the Wednesday episode, which is about Healthcare.

If you're not already listening to that podcast, definitely check it out. Next Wednesday, Shannon's

definitely going to be talking about this deal, and probably talking about it in a way with far greater

intelligence than you and I are talking about it.

Barker: Oh, easy. That's damning with faint praise.

Hill: [laughs] So, I was chatting with her before. And I said, "Is what we're seeing

with Bristol Myers the traditional," as you indicated, "they're the acquiring company,

maybe some people think they spent a little too much money and that's why the stock is down?"

She said she thought that was part of it, but also, Bristol Myers had been languishing

on its own, and there were some who thought that Pfizer might be making a bid to buy Bristol Myers.

Some of what we're probably seeing with Bristol Myers selling off today is the

"you paid too much," and some of it is, "I was hoping you guys were going to get bought."

Barker: Yeah. "You paid too much," "we hate stocks today," and "now Pfizer isn't going

to overpay for you, so we're out of here." Hill: Some people would say those three factors

make up a perfect storm. Barker: Yeah, idiots are the ones who would say that.

Speaking of idiotic notions, do you think this is the opportunity for Bristol Myers

to get rid of the Squibb in its name?

Hill: Yeah. Barker: The whole Harry Potter thing has

undermined the attractiveness of that.

Hill: Yes. In the Harry Potter universe, a squib is a person born of magical parents,

but they do not have magical abilities. Do I have that right?

Barker: You do have that right. Hill: OK. So, yes, I think you're right, in

part because some people on Twitter today were already starting to throw out polls in

terms of like, "Bristol Myers Squibb is buying Celgene. What should the new name be?

Should it be BristolGene? Should it be CelSquibb?" CelSquibb, I don't think that was getting many votes.

Barker: No. Bristol Meyers-Celgene... I don't know.

I don't care. [laughs] I've got my share of Bristol Myers to deal with now.

Hill: We're joking about this, but make no mistake, there are actual conversations taking

place at Bristol Myers Squibb headquarters in New Jersey today if they haven't been going

on already about, "What is the name going to be? What is the branding going to look like?"

Barker: Oh, yeah. Money is being spent.

And if they get it wrong, you will be there to kick them in the teeth for a long time.

Hill: I and others. [laughs] If we do anything on this podcast, it's take shots at people

who really blow it when it comes to branding. Barker: Yeah. You've won a few of those battles.

Hill: We had a couple of victories. Certainly with Tronc. The people who came up with Tronc

saw the error of their ways and went back to Tribune Media. Good for them.

Barker: Oath, is that still around? Hill: Nope. They also saw the error of their ways.

Even more quickly than the Tronc people did. They went with Verizon Media.

Barker: What's No. 1 on your hit list now? Hill: I don't know. We'll see what these

people come up with. Before we dip into the Fool mailbag,

you've been out because you've been injured. The dozens of listeners who've been wondering,

"Where's Bill Barker?" He's been on the mend.

Barker: I tweaked my leg.

Hill: I think you did more than tweak your leg. You shredded your Achilles tendon.

Barker: It's still there. Hill: It's still there, but it's repaired.

Barker: It's under a cast. Yeah. Hill: How are you feeling?

Barker: I feel fine. I feel good. It's a little annoying to be wandering around on crutches.

But other than that, I'm fine. Hill: Since this is in the wake of talking

about one of the largest pharmaceutical companies in America, I should ask, what was the best

part of the painkillers? Barker: I actually didn't need them for very long.

I didn't even need them, I think, the day after. I wasn't up and around very much.

If I had been up and around, I would have needed them. But I was just lying down pretty much,

and not in any real pain.

Hill: Nice.

Barker: So, I can't speak to the quality of the painkillers that I was on, because they

weren't killing that much pain. Which is nice. I guess that's the best part. I had pain the

moment that I heard everything pop. That was unpleasant.

Hill: Right. That sounds like the best part of painkillers, not needing them. Years ago,

when I threw out my back, I remember after a day and a half, finally seeing a doctor

and getting some medication. Once that first painkiller kicked in, after the initial,

"Oh, I feel so much better," the next thought in my head was, "Oh, this is why people get addicted

to this stuff." And I was like, "I have to get rid of these as soon as possible."

Barker: Yeah. I really didn't have any pain to speak of. Every time I got up, I had some pain,

but I didn't get up much. Hill: Nice! Yeah, you have able-bodied children

who can fetch things for you. Barker: They can fetch things for me and I can

work on a laptop and just lie around for a little while. I had to come back

in eventually. You need to get out of the house.

Hill: Absolutely. Our e-mail address is marketfoolery@fool.com.

Question from Eddy, who writes, "I have a question

about investing for my daughter. She's already out of college and currently

working full time, so she's not really a kid. She doesn't know much about investing and has

asked me to invest her savings. Do you recommend buying the same holdings you already

have for your kids or diversifying and buying companies you don't already have? She has

no interest in this topic at all, so I'm trying to decide for her."

Let me start with this: I get that she has no interest in this, Eddy, but I think this

is an opportunity to slowly bring her along and get her at least mildly interested.

It behooves her to get somewhat interested in where her investment dollars are going.

Barker: Yeah. Not knowing the specific circumstance, but seeing that she is working full time,

I would start with, is she using the company 401(k) if there is one? Hopefully there is.

If not, and even if so, is she contributing to an IRA? The specific companies is certainly

one of the prisms that our company in general looks through. A lot of the people that read

or listen to our work think in terms of individual companies. That's one way to get somebody

interested in something they know and understand. But another way is to just watch money grow.

When you first start contributing to a 401(k), you're starting at zero. You're going to see

that amount rapidly grow because you're contributing to it every two weeks, presumably.

Also, you're hopefully getting a company match.  I don't know that that's going to be the case,

or if there even is a 401(k) where this young woman is working. I hope there is. If there is,

and there's a company match, and you're not using it, that should be an easy sale.

Beyond that, of course, the value of a Roth or regular IRA. And, parents even subsidizing

their kids. If they feel like, "I can't afford to take that much money out of my paycheck,"

a little help from parents is probably more valuable. And, getting that habit started early.

Hill: In terms of specific stocks, and I think

that's another natural place for parents to look, is, "I own these stocks. I'm bullish

on these stocks. Therefore, I will buy them for my children or put them in my children's account."

That's a natural way to think. I would split the difference there, Eddy,

or at least consider splitting the difference. There may be some stocks that you own,

that you have a particular interest in, and you're particularly bullish on. Maybe those are some

that you buy on behalf of your daughter. But I'm a big believer in, the easier a business

is for a person to understand, the easier it is for them to follow how that business

is doing. So, maybe a conversation with your daughter about what she's interested in,

what she has a natural aptitude for, what her circle of competence is, and maybe buying a couple

of stocks in that direction, as well. Barker: Yeah, I think that's good advice.

To start somebody off on a company that they can't understand, biotech or anything like that,

where you don't really understand how drugs get approved, many areas of tech are

difficult for people to process. Apple little bit less so because they see the phones.

Buying something that's cheaper than it used to be is also one way to get people interested.

But, the 401(k) and Roth -- the IRA gives you the opportunity to invest in individual companies.

That's the place that I would start. To be invested in an account where you can't

really touch the money, or can't do so without a significant penalty, which is going to be

the case with a 401(k) or an IRA and knowing that the money that you put in today

is going to be compounding for roughly 40 years before it gets spent.

Hill: As good a place as any to wrap up. Thanks for being here!

Barker: Thank you! Hill: You can read more from Bill Barker

and his colleagues. Go to mfamfunds.com. As always, people on the program may have interests

in the stocks they talk about, and The Motley Fool may have formal recommendations for or against,

so don't buy or sell stocks based solely on what you hear. That's going to do it

for this edition of MarketFoolery. The show is mixed by Dan Boyd. I'm Chris Hill.

Thanks for listening! We'll see you on Monday!

For more infomation >> What Should Investors Think of Apple's Disappointing Guidance? - Duration: 23:30.

-------------------------------------------

Noticias Telemundo Mediodía, 8 de enero de 2019 | Noticias Telemundo - Duration: 21:15.

For more infomation >> Noticias Telemundo Mediodía, 8 de enero de 2019 | Noticias Telemundo - Duration: 21:15.

-------------------------------------------

Cesan a jefes de policía de Ciudad de México | Noticias Telemundo - Duration: 2:30.

For more infomation >> Cesan a jefes de policía de Ciudad de México | Noticias Telemundo - Duration: 2:30.

-------------------------------------------

Despiden a maestra que arrastró a niño autista | Noticias Telemundo - Duration: 0:41.

For more infomation >> Despiden a maestra que arrastró a niño autista | Noticias Telemundo - Duration: 0:41.

-------------------------------------------

Aumenta popularidad de música latina | Noticias Telemundo - Duration: 0:51.

For more infomation >> Aumenta popularidad de música latina | Noticias Telemundo - Duration: 0:51.

-------------------------------------------

Maestros de Los Angeles amenazan con huelga | Noticias Telemundo - Duration: 0:40.

For more infomation >> Maestros de Los Angeles amenazan con huelga | Noticias Telemundo - Duration: 0:40.

-------------------------------------------

Qual é o papel do acadêmico norte-americano no Brasil? - Duration: 1:53.

For more infomation >> Qual é o papel do acadêmico norte-americano no Brasil? - Duration: 1:53.

-------------------------------------------

Aquaman Cast - Then and Now 2019 - Duration: 3:48.

Aquaman Cast - Then and Now 2019

Subscribe to our channel by clicking the subscribe button click the bell button and enjoy the latest uploads from our channel

Oh, my baby

I'm crazy. But you've been that bad for me meatballs done. Got your feeble fly

Get to flap with me. I

Can take you down for a ride

Take you

Crosswalking they'd like

Oh, baby

So I am crazy

My baby

So, I'm crazy

We musta got your feet

You get to fly

You can take you down for right take you around

Fucking red black

Oh

My baby

Comes there in nature, so I'm crazy

What you've been that bad for me

Repost I got your feet

You'll get to flap with me. I

Can take you down for a ride

Take you

Can you cross Walking Dead lucky

For more infomation >> Aquaman Cast - Then and Now 2019 - Duration: 3:48.

-------------------------------------------

⚡Acceleration - Physics - Science - Succeed Lightning Video⚡ - Duration: 1:04.

SucceedSchool.com, learn to succeed. Acceleration. The rate of change of

velocity of an object is called acceleration. To calculate it we first

need to know how much that velocity has changed. Sometimes we represent this as

delta v and sometimes as v minus u. They both mean the same thing; subtract the

start velocity from the final velocity. Once we know how much the velocity has

changed, we then divide that number by the time it took, to find the

acceleration, so either delta v divided by t, or v minus u divided by t. The units

of acceleration are meters per second per second, or meters per second squared.

On a velocity time graph the gradient of the graph is calculated by subtracting

final velocity from initial velocity and dividing by the time taken, so the

gradient of a velocity time graph is the acceleration. This is an object

accelerating, this is one with constant positive velocity, this is one

decelerating but still moving forwards, like a car slowing down as it approaches

a junction, and this is an object with constant negative velocity, that is it's

moving backwards. To learn more about velocity time graphs please check this

video and click here to subscribe.

For more infomation >> ⚡Acceleration - Physics - Science - Succeed Lightning Video⚡ - Duration: 1:04.

-------------------------------------------

Garagistic BMW E46 FCAB (Front Control Arm Bushings) - Duration: 3:06.

Matthew: This is Matthew with Garagistic.

Thanks for joining us on the YouTube channel once again.

Today we have an e46 control arm bushing video.

Here we're gonna talk a little bit about the options 'cause they can get a little bit confusing

when ordering e46 bushings, especially for the control arm between the m3 and non-m.

Matthew: The major difference is in the polyurethane and Delrin bushings and we call them main

body bushings is what they are.

What it is, is that there is two different available sizes.

There's a 60 mm size and a 66 millimeter size.

Basically it's the bore inside your control arm mounting point.

Basically that one is fairly simple.

If you have an m3, it's 60 millimeter, if you have a non-m3, it's a 66 millimeter.

Matthew: This could be because BMW thought having more comfort by having that extra six

millimeters of material, we ended up just finding out that they were fairly consistent

with that.

The other thing though when coming to ordering this is your hex size on your control arm.

This one is not so clear because certain after market companies and after market arms ended

up mixing up the algorithm a little bit, so basically there's two different available

sizes.

There's a 22 and a 25 millimeter hex.

The easiest way to do it is to measure it.

It won't be a perfect 22 or a perfect 25, but you'll know which one you have simply

by measuring it.

What you can also do is send in the last seven of your VIN to info@garagistic.com before

ordering and we can look up and make sure you get the right one for your application.

Matthew: As you can see, these are really, really nicely machined.

We ended up machining these to fit inside of the main body bushings and that will decide

on what options you pick.

Again, we have the usual Garagistic flavors, 80a, 95a and delrin.

We also have, in this particular case, aluminum as well for full race guys, so that's very

good for the race application.

Matthew: Basically once you picked your hex size, that gets pressed into the main body

and on the other side you'll see that we have taper on here, that's to get it so that it

can basically go in there with as maximum engagement as possible and the installation

is very, very easy.

You basically, once you have your control arm off your car, I mean you can do it in

your car, but having it off of it will make it considerably easier.

Basically, this hex ends up fitting right on there, pushing on just like that.

Basically, effectively making this a cylinder instead of a hex.

That way when it's inside the bushing it can rotate.

Then using the bushing that you've selected, you can just press that on to the backend

and you're all set.

Matthew: Thanks, and if you're interested in purchasing this product, please click on

the link below.

Matthew: It was rolling off the table.

For more infomation >> Garagistic BMW E46 FCAB (Front Control Arm Bushings) - Duration: 3:06.

-------------------------------------------

cara mendapatkan uang dari android dengan safelinku - Duration: 5:58.

who have not subscribed, please subscribe first

to get notifications

don't forget to click the bell icon too

thank you

see you again friends

in njulz chanel

this time I will share tips

how to get money from an android phone

ok, open browser in android

ok,we opened

in chrome,mozila or

uc browser

I use the browser

this is friend

safelinku.com

link on deskription

how to register?

klik on register

in this

fill in your name

fill in the form completely

and chaptcha verification

submit!

i have alredy account

let's open it

ok friends

this is my balance 6,4 usd

download every day less than 80 downloads

in one day

in new account

ok, straight to the way

if we have file downloads

like me

theme file,wall paper,apk

or etc

upload your file to google drive

like this

this is file theme oppo

apk can also

copy file

turn on share link

back to safelinku.com

paste your url here

click this icon

left side of settings

and this is short link

from safelinku,copy link

and paste link in your blog,youtube deskription,

facebook

etc

like this friends

i give my short link in

youtube deskription

how to widraw?

back to safelinku

here are 3 lines

click

for widrawal

just click widraws

and

click request widraws

or add payment method

choose as you wish

paypal,local bank

bri,bca etc

all operator pulses

trypay,ovo,gopay

i try

to pulses all operator

the process of widraws 3 - 7 day

ok

this is

my tutorial

may be useful

see you again

Không có nhận xét nào:

Đăng nhận xét